A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Trial Profile

A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2018

At a glance

  • Drugs Polatuzumab vedotin (Primary) ; Bendamustine; Obinutuzumab; Rituximab
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 08 May 2018 According to a Roche media release, data from this trial will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Jun 2018).
    • 12 Dec 2017 Results of outcomes of diffuse large B cell lymphoma comparing pola+BR to BR, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 10 Dec 2017 Primary endpoint Percentage of Participants with Complete Response (CR) has been met according to a Genentech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top